NASDAQ:BVXV BiondVax Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BiondVax Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $1.16 -0.05 (-4.13%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$1.16▼$1.2550-Day Range$1.16▼$1.6552-Week Range$1.00▼$4.19Volume58,249 shsAverage Volume753,404 shsMarket Capitalization$13.17 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BVXV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address BVXV Stock Forecast (MarketRank)Overall MarketRank™1.53 out of 5 starsMedical Sector1014th out of 1,418 stocksBiological Products, Except Diagnostic Industry154th out of 216 stocksAnalyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingBiondVax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, BiondVax Pharmaceuticals has a forecasted upside of 503.4% from its current price of $1.16.Amount of Analyst CoverageBiondVax Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.1 Community Rank Outperform VotesBiondVax Pharmaceuticals has received 189 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiondVax Pharmaceuticals has received 115 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiondVax Pharmaceuticals has received 62.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BiondVax Pharmaceuticals and other stocks. Vote “Outperform” if you believe BVXV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiondVax Pharmaceuticals does not currently pay a dividend.Dividend GrowthBiondVax Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BiondVax Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.03% of the stock of BiondVax Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 2.96% of the stock of BiondVax Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BiondVax Pharmaceuticals are expected to decrease in the coming year, from ($0.41) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BiondVax Pharmaceuticals is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BiondVax Pharmaceuticals is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiondVax Pharmaceuticals has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BiondVax Pharmaceuticals (NASDAQ:BVXV)BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Read More BVXV Stock News HeadlinesJune 24, 2022 | americanbankingnews.comStockNews.com Initiates Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)June 18, 2022 | americanbankingnews.comBiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Short Interest UpdateJune 14, 2022 | americanbankingnews.comStockNews.com Begins Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)June 7, 2022 | finance.yahoo.comBiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trialJune 6, 2022 | americanbankingnews.comBiondVax Pharmaceuticals (NASDAQ:BVXV) Now Covered by StockNews.comJune 3, 2022 | seekingalpha.comBiondvax Pharmaceuticals reports Q1 resultsJune 3, 2022 | americanbankingnews.comShort Interest in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Decreases By 16.4%June 1, 2022 | investing.comBiondVax Pharma Reports Q1 ResultsJune 1, 2022 | finance.yahoo.comBiondVax Announces First Quarter 2022 Financial Results and Provides Business UpdateMay 31, 2022 | americanbankingnews.comFinancial Contrast: Mesoblast (NASDAQ:MESO) & BiondVax Pharmaceuticals (NASDAQ:BVXV)May 19, 2022 | finance.yahoo.comBiondVax to Present at H.C. Wainwright Global Investment ConferenceMay 9, 2022 | finance.yahoo.comBiondVax to Present at this week's Biomed Israel ConferenceMay 2, 2022 | finance.yahoo.comBVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BVXV CUSIPN/A CIK1611747 Webwww.biondvax.com Phone9723029302529Fax972-8930-2531Employees15Year FoundedN/ACompany Calendar Last Earnings6/01/2022Today6/24/2022Next Earnings (Estimated)8/25/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$7.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+503.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12.85 million Net MarginsN/A Pretax MarginN/A Return on Equity-304.68% Return on Assets-46.37% Debt Debt-to-Equity Ratio4.03 Current Ratio5.82 Quick Ratio5.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book1.76Miscellaneous Outstanding Shares11,354,000Free Float10,669,000Market Cap$13.17 million OptionableNot Optionable Beta2.51 BiondVax Pharmaceuticals Frequently Asked Questions Should I buy or sell BiondVax Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BiondVax Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BiondVax Pharmaceuticals stock. View analyst ratings for BiondVax Pharmaceuticals or view top-rated stocks. What is BiondVax Pharmaceuticals' stock price forecast for 2022? 1 brokers have issued 1 year price objectives for BiondVax Pharmaceuticals' shares. Their BVXV stock forecasts range from $7.00 to $7.00. On average, they expect BiondVax Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 503.4% from the stock's current price. View analysts' price targets for BiondVax Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has BiondVax Pharmaceuticals' stock price performed in 2022? BiondVax Pharmaceuticals' stock was trading at $2.35 on January 1st, 2022. Since then, BVXV stock has decreased by 50.6% and is now trading at $1.16. View the best growth stocks for 2022 here. Are investors shorting BiondVax Pharmaceuticals? BiondVax Pharmaceuticals saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 52,100 shares, a decrease of 15.4% from the May 15th total of 61,600 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is presently 0.0 days. View BiondVax Pharmaceuticals' Short Interest. When is BiondVax Pharmaceuticals' next earnings date? BiondVax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 25th 2022. View our earnings forecast for BiondVax Pharmaceuticals. How were BiondVax Pharmaceuticals' earnings last quarter? BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) posted its quarterly earnings results on Wednesday, June, 1st. The company reported ($0.20) EPS for the quarter. View BiondVax Pharmaceuticals' earnings history. Who are BiondVax Pharmaceuticals' key executives? BiondVax Pharmaceuticals' management team includes the following people: Mr. Amir Reichman M.B.A., M.Sc., CEO & Director (Age 46)Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA, Chief Financial Officer (Age 52)Mr. Elad Mark B.Sc., Eng., M.B.A., Chief Operating Officer (Age 40)Dr. Tamar Ben-Yedidia Ph.D., Chief Scientist (Age 58)Mr. Joshua E. Phillipson B.Sc., M.B.A., Director of Bus. Devel. & Investor RelationsMs. Moran Ahdout Fruchter L.L.B., Chief of StaffMs. Dalit Weinstein Fischer, Head of Technical R&D Who are some of BiondVax Pharmaceuticals' key competitors? Some companies that are related to BiondVax Pharmaceuticals include Protalix BioTherapeutics (PLX), Protalix BioTherapeutics (PLX), Senti Biosciences (SNTI), MiNK Therapeutics (INKT), IN8bio (INAB), PharmaCyte Biotech (PMCB), OKYO Pharma (OKYO), Evaxion Biotech A/S (EVAX), AVROBIO (AVRO), Cognition Therapeutics (CGTX), Pluristem Therapeutics (PSTI), Xtant Medical (XTNT), AIM ImmunoTech (AIM), CASI Pharmaceuticals (CASI) and Entera Bio (ENTX). View all of BVXV's competitors. What other stocks do shareholders of BiondVax Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA). When did BiondVax Pharmaceuticals IPO? (BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO. What is BiondVax Pharmaceuticals' stock symbol? BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV." How do I buy shares of BiondVax Pharmaceuticals? Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BiondVax Pharmaceuticals' stock price today? One share of BVXV stock can currently be purchased for approximately $1.16. How much money does BiondVax Pharmaceuticals make? BiondVax Pharmaceuticals (NASDAQ:BVXV) has a market capitalization of $13.17 million. The company earns $-12.85 million in net income (profit) each year or ($0.77) on an earnings per share basis. How many employees does BiondVax Pharmaceuticals have? BiondVax Pharmaceuticals employs 15 workers across the globe. How can I contact BiondVax Pharmaceuticals? BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The official website for BiondVax Pharmaceuticals is www.biondvax.com. The company can be reached via phone at 9723029302529, via email at [email protected], or via fax at 972-8930-2531. This page (NASDAQ:BVXV) was last updated on 6/24/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
